| Literature DB >> 26448266 |
Sevket Balta1, Dimitri P Mikhailidis2, Sait Demirkol3, Cengiz Ozturk3, Turgay Celik3, Atila Iyisoy3.
Abstract
Endothelial dysfunction is considered as an early change in atherogenesis. Raised levels of systemic inflammatory markers are associated with cardiovascular disease (CVD). Endocan (previously known as endothelial cell specific molecule-1, ESM-1), is a potential immunoinflammatory marker that may be linked to CVD. Endocan is released by vascular endothelial cells in several organs. Endocan may play an important role in regulating cell adhesion and raised plasma levels may reflect endothelial dysfunction. Endocan levels are elevated in conditions such as chronic kidney disease, renal transplant rejection, tumor progression and hypertension. Endocan is a potential inflammatory and CVD marker. Further studies are needed to assess the relevance of endocan in clinical practice.Entities:
Keywords: Atherosclerosis; Cell adhesion; Endocan; Endothelial dysfunction; Inflammation
Mesh：
Substances：
Year: 2015 PMID： 26448266 DOI： 10.1016/j.atherosclerosis.2015.09.030
Source DB: PubMed Journal: Atherosclerosis ISSN： 0021-9150 Impact factor: 5.162